AnaptysBio Completes Spinoff of First Tracks Biotherapeutics; Shares Surge

MT Newswires Live
04/20

AnaptysBio (ANAB) said Monday that it has completed the spinoff of its biopharma operations business First Tracks Biotherapeutics.

Under the terms of the spinoff, Anaptys shareholders received one share of First Tracks for every share of Anaptys owned as of the close of business on April 6. First Tracks Bio common stock were set to begin trading Monday on the Nasdaq Global Select Market under the ticker symbol "TRAX."

The company said it will now exclusively manage its financial collaborations with GSK (GSK) and Vanda for cancer medicine Jemperli and generalized pustular psoriasis treatment imsidolimab, respectively.

Shares of AnaptysBio were up close to 8% in recent trading on Monday.

Price: 48.39, Change: +3.39, Percent Change: +7.53

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10